Latest Protein C Stories
PRINCETON, N.J., Aug. 13, 2012 /PRNewswire/ -- Laureate Biopharma is pleased to announce its successful collaboration with its client, ZZ Biotech, on process development and production of a new potential therapeutic for ischemic stroke. The drug, known as 3K3A-APC, is a form of activated human Protein C whose molecular structure has been intentionally modified to remove the undesirable side effect of bleeding. ZZ Biotech recently announced the start of Phase 1 trials with this...
New research in Nature Medicine shows that boosting a protein pathway in the body's blood making system protects mice from otherwise fatal radiation poisoning. Scientists in the multi-institutional study – posted online by the journal on June 24 – say their findings open the potential for new treatments against radiation toxicity during cancer treatment or environmental exposures – such as in a nuclear explosion or accident. By identifying a target-specific intervention to protect...
CINCINNATI, June 24, 2012 /PRNewswire-USNewswire/ --The following is being released today by the Cincinnati Children's Hospital Medical Center: (Logo: http://photos.prnewswire.com/prnh/20110406/MM79025LOGO) New research in Nature Medicine shows that boosting a protein pathway in the body's blood making system protects mice from otherwise fatal radiation poisoning. Scientists in the multi-institutional study - posted online by the journal on June 24 - say their findings open the...
Eight Centers in North America and Europe Participate in a Search for Biomarker VANCOUVER, Oct. 11, 2011 /PRNewswire/ - BC-based biotech company Sirius Genomics today announced the launch of a large, international study that enlists the help of some of the world's top acute care centers in a hunt for a biomarker that would predict outcome from a controversial treatment using activated protein C. With an estimated 18 million global cases annually, sepsis is associated with...
Research harnesses enzyme's anti-blood clotting abilitiesIn research led by a Saint Louis University investigator, molecular biologists have discovered a way to harness the enzyme thrombin's anti-blood clotting properties. The finding opens the door to new medications that will treat diseases related to thrombosis, the presence of blood clots in blood vessels, which is responsible for nearly a third of all deaths in the U.S."Thrombosis is one of the most prevalent causes of fatal...
ST. LOUIS, June 18 /PRNewswire-USNewswire/ -- In research led by a Saint Louis University investigator, molecular biologists have discovered a way to harness the enzyme thrombin's anti-blood clotting properties. The finding opens the door to new medications that will treat diseases related to thrombosis, the presence of blood clots in blood vessels, which is responsible for nearly a third of all deaths in the U.S. "Thrombosis is one of the most prevalent causes of fatal disease," said lead...
ST. LOUIS, May 7 /PRNewswire/ -- Lee Biosolutions has announced that it will increase its C-Reactive Protein product line to include recombinant C-Reactive Protein. C-Reactive Protein is a protein found in the blood that operates as a marker for inflammation, meaning its presence indicates an increased state of inflammation in the body. Inflammation is a normal response to a number of physical states including injury, fever and infection. Inflammation is also believed to play a role in...
- Court Orders Confiscation of Diagnostica Stago's Inventory of Infringing Products - BEDFORD, Mass., May 4 /PRNewswire/ -- Instrumentation Laboratory Company and its parent company Instrumentation Laboratory S.p.A. (IL) today announced that the Paris First Level Civil Court determined that Diagnostica Stago infringed the French counterparts of two European patents licensed exclusively to IL, and committed acts of unfair competition due to denigrating advertisements. As a result, the...
By Lijfering, Willem M Sprenger, Herman G; Georg, Rita R; van der Meulen, Piet A; van der Meer, Jan BACKGROUND: HIV-infected patients are at increased risk of venous and arterial thrombosis. We hypothesized that acquired thrombophilic abnormalities that could predispose to thrombosis are most pronounced in patients in advanced stages of HIV infection. METHODS: We included 109 consecutive HIV-infected patients in the study and tested them twice for currently known thrombophilic abnormalities...
